The other concept, pursued by Pfizer, Japan's Ono Pharmaceutical, the AstraZeneca-Renovis partnership and numerous other firms, is to find a brain-cell protector that could be used to stabilize nerve cells and prevent further damage.
TiVo has increased research and development by 36% in the past six months to ensure it can handle the software licensing deals it's been rapidly signing with smaller cable firms such as RCN, Charter, Spain's Ono, France's Canal and Suddenlink, all of which want to use TiVo to leapfrog into the world of advanced television.